, Singapore
380 views
Photo by Julia Koblitz via Unsplash

UltraGreen.ai gains Singapore approval for Verdye in regional push

The regulatory clearance anchors UltraGreen.ai's Southeast Asia expansion.

UltraGreen.ai has secured regulatory approval in Singapore for Verdye, or indocyanine green for injection, which will support its expasion in Southeast Asia.

In a press release, the company said the approval gives the company access to Singapore’s healthcare system, noting Singapore acts as a centre for clinical practice and regional influence in healthcare adoption. 

The approval also supports its commercialisation efforts and partnerships with hospitals and healthcare institutions in the city-state.

Verdye is used in fluorescence-guided surgery with indocyanine green, applied in oncology, colorectal, reconstructive, and vascular procedures.

UltraGreen.ai develops a fluorescence-guided surgery platform combining pharmaceutical products, imaging hardware, and artificial intelligence-based data tools for surgical decision-making and procedural standardisation.

The company said the platform supports wider adoption of fluorescence-guided surgery across procedures.

Ravi Sajwan, CEO of UltraGreen.ai, said Singapore serves as a strategic market due to its healthcare system and regional role in clinical adoption across Southeast Asia, adding that the approval supports regulatory execution and the company’s regional strategy.

Verdye is approved in 41 countries, whilst the IC-Flow imaging system is approved in 45 markets.

UltraGreen.ai also referenced its recent initial public offering and regulatory approval of Verdye in the Philippines as part of its Southeast Asia expansion.

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.


The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.


So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Top News

The Assembly Place’s H1 profit rises 80.7% to $2.2m
The community-living operator expanded its managed portfolio to 3,520 keys during the period.
ONE Pass holders rise to 8,500 in 2025
About 70% worked in finance, information and communication, and professional services.
STI ETF retail assets climb fivefold to $4.2b: SGX
Retail investors have net bought nearly $20b of Singapore equities since 2020.
Stocks

Exclusives

Singapore targets captive insurance growth
Smaller companies could gain a lower-cost way to manage risk.
Earlybird AI targets SME accounting
Its founder says small businesses need finance teams without adding headcount.